References
Biopharmaceutical Process Extractables Core Team. Evaluation of extractables from product-contact surfaces. BioPharm International 2002; 15(12):22-34.
ARTICLES
Biopharmaceutical Process Extractables Core Team. Evaluation of extractables from product-contact surfaces.
BioPharm International
2002; 15(12):22-34.
Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 2003; 20(9):1325-1336.
Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 1993; 10:307-377.
Crowe JH, Crowe LM, Carpenter JF. Preserving dry biomaterials: the water replacement hypothesis, part 1. BioPharm 1993; 6(3):28.
Crowe JH, Crowe LM, Carpenter JF. Preserving dry biomaterials: the water replacement hypothesis, part 2. BioPharm 1993; 6(4):40.
Faulkner J. The evolving role of product characterization during development.BioPharm 2000; 13(6):26.
Franks F, Hatley RHM, Mathias SF. Materials science and the production of shelf-stable biologicals. BioPharm 1991; 4(8):38.
Imensek M. Sterile fill facilities: problems and resolutions. BioPharm International 2003; 16(9):44-54.
Katre N. Lipid-based multivesicular carriers for sustained delivery of therapeutic proteins and peptides. BioPharm International 2001; 14(3 supplement):8.
Kerr AP, et al. An early warning tool for pharmaceutical development. BioPharm 1992; 5(2):24.
Kleinert HD, Baker WR, Stein HH. Orally bioavailable peptidelike molecules: a case history. BioPharm 1993; 6(1):36.
Krishnamurthy R. Protein stability in pulmonary delivery formulations: a review. BioPharm 1999; 12(3):34.
Krishnamurthy R, Manning MC. The stability factor: importance in formulation development. Curr Pharm Biotech 2002; 3:361-371.
Lakings DB. Making a successful transition from drug discovery to drug development, part 1. BioPharm 1995; 8(7):20.
Lee VHL. Oral route of peptide and protein drug delivery. BioPharm 1992; 5(5):39.
Lee VHL. Trends in peptide and protein drug delivery. BioPharm1991; 4(2):22.
Lee WA, Longenecker JP. Intranasal delivery of proteins and peptides. BioPharm 1988; 1(3):30.
Lee WA. Permeation enhancers for the nasal delivery of protein and peptide therapeutics. BioPharm 1990; 3(9):22.
Patapoff TW, Overcashier DE. The importance of freezing on lyophilization cycle development. BioPharm 2002; 15(3):16-21, 72.
Pelegrin M, et al. Encapsulated antibody-producing cells for long-term passive immunotherapy. BioPharm 1999; 12(10):32.
Pikal MJ. Freeze-drying of proteins, part 2: formulation selection. BioPharm 1990; 3(8):26.
Roser B. Trehalose drying: a novel replacement for freeze-drying. BioPharm 1991; 4(7):47.
Sanghvi P, Banakar UV. Ultrasonics: principles and biomedical applications. BioPharm 1991; 4(7):32.
Schmidt DJ, Akers MJ. Cryogranulation: a potential new final process for bulk drug substances. BioPharm 1997; 10(4):28.
Scott C. Formulation case studies: a tutorial. BioPharm 2001; 14(8):34-35.
Strattan CE. Cyclodextrins and biological macromolecules. BioPharm 1991; 4(9):44.
Talsma H, Crommelin DJA. Liposomes as drug delivery systems, part 2: characterization. BioPharm 1992; 5(9):38.
Talsma H, Crommelin DJA. Liposomes as drug delivery systems, part 3: stabilization. BioPharm 1993; 6(2):40.
Webb SD, Webb JN, Hughes TG, Sesin DF, Kincaid AC. Freezing bulk-scale biopharmaceuticals using common techniques — and the magnitude of freeze-concentration. BioPharm 2002; 15(5):22-34.
Weiner AL. Developing lipid-based vehicles for peptide and protein drugs. BioPharm 1990; 3(2):27.
Weiner AL. Lipid-based vehicles for peptide and protein drugs, part 2: manufacturing variables. BioPharm 1990; 3(3):16.
BOOKS
Ahern TJ, Manning M, eds.
Stability of protein pharmaceuticals, part A: chemical and physical pathways of protein degradation
. Pharmaceutical biotechnology series, volume 2. New York: Plenum Press; 1992.
Ahern TJ, Manning M, eds. Stability of protein pharmaceuticals, part B: in vivo pathways of degradation and strategies for protein stabilization. Pharmaceutical biotechnology series, volume 2. New York: Plenum Press; 1992.
Avis KE, Wu VL. Biotechnology and biopharmaceutical manufacturing, processing, and preservation. Drug manufacturing technology series, volume 2. Buffalo Grove (IL):Interpharm Press; 1996.
Banga AK. Electrically assisted transdermal and topical drug delivery. London: Taylor & Francis; 1998.
Bontempo J, ed. Development of biopharmaceutical parenteral dosage forms. New York: Marcel Dekker; 1997.
Carpenter, JF, Chang BS, Garzon-Rodriguez W, Randolph TW. Rational design of stabilized lyophilized protein formulations: theory and practice. In: Carpenter JF, Manning MC, editors. Rational design of stable protein formulations: theory and practice. New York: Kluwer/Plenum Press; 2002. p. 109-133.
DeSain C. Documentation basics that support good manufacturing practices. Cleveland (OH): Advanstar Communications; 1993.
Hider RC, Barlow D. Polypeptide and protein drugs: production, characterization, and formulation. Ellis Horwood Ltd: Chichester UK; 1991.
Huxsoll JF. Quality assurance for biopharmaceuticals. New York: John Wiley & Sons; 1994.
Kibbe AH, ed. Handbook of pharmaceutical excipients. Third Ed. Washington, DC: American Pharmaceutical Association; 2000.
McNally EJ, ed. Protein formulation and delivery. New York: Marcel Dekker; 2000.
Rowe RC, Roberts RJ. Intelligent software for product formulation. London: Taylor & Francis; 1998.
Saeb-Parsy K, et al., eds. Instant pharmacology. New York: John Wiley & Sons; 1999.
Wang YJ, Pearlman R, eds. Stability and characterization of protein and peptide drugs: case histories. Pharmaceutical biotechnology series, volume 5. New York: Plenum Press; 1993.
Wang YJ, Pearlman R, eds. Formulation, characterization, and stability of protein drugs: case histories. Pharmaceutical biotechnology series, volume 9. New York: Plenum Press; 1996.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
Top 10 Cleanroom Problems That Can Be Prevented via Preventative Maintenance (May 2025)
May 16th 2025Cleanrooms require strict environmental control to maintain sterility, prevent contamination, and ensure seamless operations. Without a proactive preventative maintenance (PM) program, various issues can arise, leading to costly downtime, contamination risks, and operational inefficiencies. Below are ten common cleanroom problems that can be effectively mitigated through proper PM practices.
